CLINICAL AND LABORATORY CHARACTERIZATION IN PATIENTS WITH OMICRON B.1.1.529 VARIANT OF COVID 19 IN ECUADOR.

Volume 6, Issue 2, April 2022     |     PP. 27-33      |     PDF (208 K)    |     Pub. Date: May 8, 2022
DOI: 10.54647/pm31166    95 Downloads     106571 Views  

Author(s)

Ángel Santillán Haro, Médico Internista Hospital General Docente de Calderón, Quito-Ecuador

Abstract
The first case of the Omicron variant in the world was detected on November 9, 2021 in South Africa. The World Health Organization on November 26, 2021 notifies as a variant of concern.
The first case of Omicron B.1.1.529 was detected in Ecuador on December 14, 2021, announced by the Minister of Public Health Ximena Garzón. The patient infected with the new variant of Sars Cov2 was a 48-year-old Ecuadorian who traveled to South Africa for research and returned to Ecuador on December 10, 2021.
On December 22, 2021, in the city of Quito in Ecuador, the author attended the first 2 patients of SarsCov2 variant Omicron sequenced by the Ministry of Health of Ecuador at the Medical Systems Medical Center of the San Francisco de Quito University.

Keywords
Omicron B.1.1.529, Covid-19

Cite this paper
Ángel Santillán Haro, CLINICAL AND LABORATORY CHARACTERIZATION IN PATIENTS WITH OMICRON B.1.1.529 VARIANT OF COVID 19 IN ECUADOR. , SCIREA Journal of Medicine. Volume 6, Issue 2, April 2022 | PP. 27-33. 10.54647/pm31166

References

[ 1 ] https://www.salud.gob.ec/ecuador-confirma-p rimercasoomicron/#:~:text=En%20Ecuador%20se%20detect%C3%B3%20el,noviembre%20del%20a%C3%B1o%20en%20curso.
[ 2 ] Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 variant of concern Omicron (B.1.1.529): risk assessment, January 6, 2022. Toronto, ON: Queen's Printer for Ontario; 2022.
[ 3 ] UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England: technical briefing: update on hospitalisation and vaccine effectiveness for Omicron OC21NOV-01 (B.1.1.529) [Internet]. London: Crown Copyright; 2021 [cited 2022 Jan 04]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/fil e/1044481/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf
[ 4 ] Carrazco-Montalvo A, Armendáriz-Castillo I, Tello CL, Morales D, ArmasGonzalez R, Guizado- Herrera D, León-Sosa A, Ramos-Sarmiento D, Fuertes B, Patino L, USFQConsortium, First detection of SARS-CoV-2 variant B.1.1.529 (Omicron) in Ecuador, New Microbes and New Infections, https://doi.org/10.1016/j.nmni.2022.100951.
[ 5 ] Peacock TP, Brown JC, Zhou J, Thakur N, Newman J, Kugathasan R, et al. The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. bioRxiv [Preprint]. 2022. DOI: 10.1101/2021.12.31.474653. Available at: https://www.biorxiv.org/content/10.1101/2021.12.31.474653v1.abstract.
[ 6 ] National Institute of Infectious Diseases Disease Control and Prevention Center, National Center for GlobalHealth and Medicine. Active epidemiological investigation on SARS-CoV-2 infection caused by Omicronvariant (Pango lineage B.1.1.529) in Japan: preliminary report on infectious period. Tokyo: NIID; 2022.Available at: https://www.niid.go.jp/niid/en/2019-ncov-e/10884-covid19-66-en.htm
[ 7 ] Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. JAMA. 2022;327(6):583-584.
[ 8 ] Public Health Ontario. Early dynamics of Omicron in Ontario, November 1 to December 16, 2021. Accessed December 24, 2021. https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-early-dynamics-omicron-ontario-epi-summary.pdf
[ 9 ] Jansen Lauren, B.1.1.529 (Omicron) variant Cluster – Nebraska, November – December 2021CDC, Diciembre 2021.